Drugmakers Set for Multiple Myeloma Showdown at Hematology Event
Source: Science Photo Library/Brand X via Getty Images
This article is for subscribers only.
The medical and investment communities will come together to see the latest in treating diseases of the blood including cancer, sickle-cell disease and hemophilia when the American Society of Hematology, or ASH, four-day annual meeting kicks off Saturday in San Diego.
Initial results from a late-breaking abstract ahead of the meeting for AbbVie Inc.’s Imbruvica as a first-line of treatment in chronic lymphocytic leukemia have done little to revive shares, despite what Leerink analyst Geoffrey Porges called “remarkable efficacy” that looks better than the current standard of care. Johnson & Johnson and Genmab will also present promising data for Darzalex in multiple myeloma.